Zhang JX, Shugarman LR. Value-based payment and financing for cell and gene therapies: challenges and potential solutions. J Med Econ. 2024;27:678–81. https://doi.org/10.1080/13696998.2024.2346406.
Fox TA, Booth C. Improving access to gene therapy for rare diseases. Dis Model Mech. 2024;17:dmm050623. https://doi.org/10.1242/dmm.050623.
Lee TL, Sawai T. Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes. Front Genet. 2024;15:1381172. https://doi.org/10.3389/fgene.2024.1381172.
Mackall CL, Bollard CM, Goodman N, Carr C, Gardner R, Rouce R, et al. Enhancing pediatric access to cell and gene therapies. Nat Med. 2024;30:1836–46. https://doi.org/10.1038/s41591-024-03035-1.
Kliegman M, Zaghlula M, Abrahamson S, Esensten JH, Wilson RC, Urnov FD, et al. A roadmap for affordable genetic medicines. Nature. 2024;634:307–14. https://doi.org/10.1038/s41586-024-07800-7.
Urnov FD. Give Cas a chance: An actionable path to a platform for CRISPR cures. CRISPR J. 2024;7:212–9. https://doi.org/10.1089/crispr.2024.0082.
Citeline Pharma Intelligence. Pharmaprojects. Citeline. 2024. https://www.citeline.com/en/products-services/clinical/pharmaprojects. Accessed 23 September 2024.
American Society of Gene & Cell Therapy (ASGCT). Gene, cell, & RNA therapy landscape: Q1 2024 quarterly data report. ASGCT. 2024. https://asgct.org/global/documents/asgct-citeline-q1-2024-report.aspx. Accessed 23 September 2024.
Novartis. Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA. Novartis. 2023. https://www.novartis.com/news/media-releases/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma. Accessed 23 September 2024.
Novartis AG. Novartis annual report 2022. Novartis. 2022. https://www.novartis.com/sites/novartiscom/files/novartis-annual-report-2022.pdf. Accessed 23 September 2024.
Institute for Clinical and Economic Review (ICER). 2020-3 Value assessment framework. ICER. 2022. https://icer.org/wp-content/uploads/2020/11/ICER_2020_2023_VAF_02032022.pdf. Accessed 23 September 2024.
Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024;11:425–42. https://doi.org/10.3233/JND-230122.
Gemeinsamer Bundesausschuss (G-BA). Neue Arzneimittel: Studien im Rahmen der anwendungsbegleitenden Datenerhebung [New medicinal products: studies as part of the post-marketing data collection] [Website in German]. G-BA. 2023. https://www.g-ba.de/studien/abd/. Accessed 23 September 2024.
World Health Organization (WHO). Fad or fabulous? Assessing value of medicines using HTA to inform pricing. WHO. 2023. https://cdn.who.int/media/docs/default-source/mhp-hps-aap/webinar-slides—2023-04.pdf. Accessed 23 September 2024.
Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, et al. Outcomes-based contracting experience: Research findings from U.S. and European stakeholders. J Manag Care Spec Pharm. 2017;23:1018–26. https://doi.org/10.18553/jmcp.2017.23.10.1018.
Kandil AM. Egypt to treat muscular atrophy patients starting next week as per Sisi’s directives. Egypt Today. 2021. https://www.egypttoday.com/Article/1/105543/Egypt-to-treat-muscular-atrophy-patients-starting-next-week-as. Accessed 23 September 2024.
Navlin Daily. Argentina to set up risk-sharing agreement for Zolgensma. 2022. https://www.navlindaily.com/article/12340/argentina-to-set-up-risk-sharing-agreement-for-zolgensma. Accessed 23 September 2024.
Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Financ Econ. 2003;3:183–205. https://doi.org/10.1023/a:1025384819575.
Chalkidou K, Claxton K, Silverman R, Yadav P. Value-based tiered pricing for universal health coverage: an idea worth revisiting. Gates Open Res. 2020;4:16. https://doi.org/10.12688/gatesopenres.13110.3.
World Health Organization (WHO). WHO guideline on country pharmaceutical pricing policies. WHO. 2020. https://www.who.int/publications/i/item/9789240011878. Accessed 23 September 2024.
Haute Autorité de Santé. Early access to medicinal products. Haute Autorité de Santé. 2023. https://www.has-sante.fr/jcms/r_1500918/en/early-access-to-medicinal-products. Accessed 23 September 2024.
Government of Alberta. Interim access to Zolgensma for Alberta children. Government of Alberta. 2021. https://www.alberta.ca/release.cfm?xID=77144B2CCA396-B35D-0296-525B872E969AD6C3. Accessed 23 September 2024.
Novartis Pharmaceuticals, Inc. AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA). Novartis. 2020. https://www.novartis.com/news/media-releases/avexis-receives-ec-approval-and-activates-day-one-access-program-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma. Accessed 23 September 2024.
Sindusfarma. Advanced therapies. Sindusfarma. 2021. https://sindusfarma.org.br/uploads/files/229d-gerson-almeida/Publicacoes_PPTs/Revista_Advanced_Therapies_21_.pdf. Accessed 23 September 2024.
Brown C, Choubey D, Taylor BK. Orphan Drug Pricing Comparisons in Low-, Middle-, and High-Income Countries. EE274. Presented at ISPOR Europe, November 6–9, 2022, Vienna, Austria.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41434-024-00509-2